StockData
Lexaria Bioscience Corp. logo

Lexaria Bioscience Corp. (LEXX) stock

LEXXNasdaqPharmaceutical PreparationsFiscal year ends August 31
Financials through Q3 FY2026, quarter ended May 31, 2026Last filing: 10-Q on Jul 13, 2026Score 8/30
$4.18−0.23 (-5.22%)

Close on Nov 17, 2026Market cap $103.61MP/E –Yield –

Lexaria Bioscience operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Lexaria Bioscience's operating cash flow for the twelve months ending May 31, 2026 was -$7.43M. For fiscal 2025 it was -$10.45M. The highest annual figure on record is $321.00K in fiscal 2013.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Aug 31, 2025-$10.45M–
FY2024Aug 31, 2024-$4.96M–
FY2023Aug 31, 2023-$5.88M–
FY2022Aug 31, 2022-$4.88M–
FY2021Aug 31, 2021-$3.99M–
FY2020Aug 31, 2020-$2.62M–
FY2019Aug 31, 2019-$3.01M–
FY2018Aug 31, 2018-$2.52M–
FY2017Aug 31, 2017-$1.55M–
FY2016Aug 31, 2016-$660.86K–
FY2015Aug 31, 2015-$1.50M-567.6%
FY2013Oct 31, 2013$321.00K+136.1%
FY2012Oct 31, 2012$135.94K+23.8%
FY2011Oct 31, 2011$109.84K–
FY2010Oct 31, 2010-$330.34K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026May 31, 2026-$1.64M–
Q2 FY2026CQ1 2026Feb 28, 2026-$2.16M–
Q1 FY2026CQ4 2025Nov 30, 2025-$984.10K–
Q4 FY2025CQ3 2025Aug 31, 2025-$2.64M–
Q3 FY2025CQ2 2025May 31, 2025-$3.58M–
Q2 FY2025CQ1 2025Feb 28, 2025-$1.50M–
Q1 FY2025CQ4 2024Nov 30, 2024-$2.73M–
Q4 FY2024CQ3 2024Aug 31, 2024-$1.89M–
Q3 FY2024CQ2 2024May 31, 2024-$1.27M–
Q2 FY2024CQ1 2024Feb 29, 2024-$619.61K–
Q1 FY2024CQ4 2023Nov 30, 2023-$1.18M–
Q4 FY2023CQ3 2023Aug 31, 2023-$1.62M–
Q3 FY2023CQ2 2023May 31, 2023-$1.79M–
Q2 FY2023CQ1 2023Feb 28, 2023-$1.23M–
Q1 FY2023CQ4 2022Nov 30, 2022-$1.25M–
Q4 FY2022CQ3 2022Aug 31, 2022-$1.18M–
Q3 FY2022CQ2 2022May 31, 2022-$1.26M–
Q2 FY2022CQ1 2022Feb 28, 2022-$1.28M–
Q1 FY2022CQ4 2021Nov 30, 2021-$1.17M–
Q4 FY2021CQ3 2021Aug 31, 2021-$1.11M–
Q3 FY2021CQ2 2021May 31, 2021-$1.16M–
Q2 FY2021CQ1 2021Feb 28, 2021-$911.25K–
Q1 FY2021CQ4 2020Nov 30, 2020-$809.53K–
Q4 FY2020CQ3 2020Aug 31, 2020-$639.35K–
Q3 FY2020CQ2 2020May 31, 2020-$670.48K–
Q2 FY2020CQ1 2020Feb 29, 2020-$753.88K–
Q1 FY2020CQ4 2019Nov 30, 2019-$555.08K–
Q4 FY2019CQ3 2019Aug 31, 2019-$736.61K–
Q3 FY2019CQ2 2019May 31, 2019-$1.10M–
Q2 FY2019CQ1 2019Feb 28, 2019-$603.26K–
Q1 FY2019CQ4 2018Nov 30, 2018-$564.31K–
Q4 FY2018CQ3 2018Aug 31, 2018-$837.06K–
Q3 FY2018CQ2 2018May 31, 2018-$559.73K–
Q2 FY2018CQ1 2018Feb 28, 2018-$600.87K–
Q1 FY2018CQ4 2017Nov 30, 2017-$520.32K–
Q4 FY2017CQ3 2017Aug 31, 2017-$353.34K–
Q3 FY2017CQ2 2017May 31, 2017-$603.50K–
Q2 FY2017CQ1 2017Feb 28, 2017-$488.09K–
Q1 FY2017CQ4 2016Nov 30, 2016-$100.99K–
Q4 FY2016CQ3 2016Aug 31, 2016-$260.77K–

More Lexaria Bioscience figures

See a number that looks wrong?